Michael Kuran, Founder Mr Kuran founded Artemisia BioMedical, Inc in 2006, and has over 20 years of years of senior management experience in the biopharma industry. He is concurrently VP of AVM Biotechnology (Seattle, WA), and CEO of ACLIRES International Ltd, a global CRO service provider with GCP-certified clinical units in Latin America and Southeast Asia. Prior to his role as CEO of Artemisia BioMedical, he held senior management positions with ZymoGenetics, Inc (Seattle, WA) and Novo Nordisk and IMS Health Ltd (Tokyo, Japan). Mr Kuran speaks Japanese and holds a BA degree from the University of Michigan, Ann Arbor. He has also participated in the Biotechnology Project Management Certificate Program managed jointly by the University of Washington, Seattle and University of California San Diego, and he attended the Executive MBA program at Temple University, Tokyo campus.
Woerner P. Meehan, PhD, President Dr Meehan is a physiologist with over 20 years of experience in managing studies of animal models of disease for drug development. He previously worked at ZymoGenetics, Inc to develop models of vascular occlusion and evaluated the efficacy of drugs in maintaining blood flow through blood vessels. He has analyzed preclinical models required for FDA approval and formulated potential clinical pathways for drug development. At the University of Southern California and University of California, Los Angeles, Dr Meehan investigated drugs designed to inhibit the proliferative stages of atherosclerosis. He devised murine models of accelerated atherosclerosis and investigated the effect on the whole animal of preventing the formation of fatty plaques. Dr Meehan received a PhD in Physiology and Biophysics from the University of Southern California.